S-2E 

S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research^[1][2].

In the liver, S-2E is converted into its active metabolite, S-2E-CoA. S-2E-CoA noncompetitively inhibits the enzymatic activities of both 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase at K_i=18.11 μM and K_i=69.2 μM, respectively^[1].
S-2E (3-30 mg/kg) given orally suppresses the secretion rate of very-low-density lipoprotein (VLDL)-cholesterol and triglyceride in Triton WR-1339-injected rats. Furthermore, S-2E lowers the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

367.44

C₂₂H₂₅NO₄

155730-92-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Koichi Ohmori, et al. Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Pharmacol. 2003 Jun 13;471(1):69-76.  [Content Brief]

  [2]. K Ohmori, et al. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. Metabolism. 2004 May;53(5):680-5.  [Content Brief]